X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare VENUS REMEDIES with WYETH LTD - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

VENUS REMEDIES vs WYETH LTD - Comparison Results

WYETH LTD 
   Change

Wyeth Limited is the 51% subsidiary of Wyeth, US and is the sixth largest company among multinationals with revenues of Rs 2.9 bn in FY07. The company derives its revenues from pharmaceutical and OTC segments with focus on various therapeutic areas s... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    VENUS REMEDIES WYETH LTD VENUS REMEDIES/
WYETH LTD
 
P/E (TTM) x -8.2 27.7 - View Chart
P/BV x 0.1 5.3 2.4% View Chart
Dividend Yield % 0.0 1.3 -  

Financials

 VENUS REMEDIES   WYETH LTD
EQUITY SHARE DATA
    VENUS REMEDIES
Mar-17
WYETH LTD
Mar-13
VENUS REMEDIES/
WYETH LTD
5-Yr Chart
Click to enlarge
High Rs1431,044 13.7%   
Low Rs65818 7.9%   
Sales per share (Unadj.) Rs324.2298.6 108.6%  
Earnings per share (Unadj.) Rs6.457.2 11.2%  
Cash flow per share (Unadj.) Rs40.658.4 69.5%  
Dividends per share (Unadj.) Rs017.00 0.0%  
Dividend yield (eoy) %01.8 0.0%  
Book value per share (Unadj.) Rs366.0249.5 146.7%  
Shares outstanding (eoy) m12.3422.72 54.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.33.1 10.3%   
Avg P/E ratio x16.216.3 99.6%  
P/CF ratio (eoy) x2.615.9 16.1%  
Price / Book Value ratio x0.33.7 7.6%  
Dividend payout %029.7 0.0%   
Avg Mkt Cap Rs m1,28221,157 6.1%   
No. of employees `0000.90.5 183.5%   
Total wages/salary Rs m251400 62.8%   
Avg. sales/employee Rs Th4,430.113,787.4 32.1%   
Avg. wages/employee Rs Th278.0813.0 34.2%   
Avg. net profit/employee Rs Th87.62,643.3 3.3%   
INCOME DATA
Net Sales Rs m4,0006,783 59.0%  
Other income Rs m23353 6.4%   
Total revenues Rs m4,0237,136 56.4%   
Gross profit Rs m7851,617 48.5%  
Depreciation Rs m42227 1,585.0%   
Interest Rs m3446 6,249.1%   
Profit before tax Rs m421,938 2.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-5 0.0%   
Tax Rs m-37632 -5.9%   
Profit after tax Rs m791,301 6.1%  
Gross profit margin %19.623.8 82.3%  
Effective tax rate %-87.932.6 -269.4%   
Net profit margin %2.019.2 10.3%  
BALANCE SHEET DATA
Current assets Rs m2,6066,984 37.3%   
Current liabilities Rs m1,9802,056 96.3%   
Net working cap to sales %15.672.6 21.5%  
Current ratio x1.33.4 38.7%  
Inventory Days Days12899 129.2%  
Debtors Days Days4324 180.2%  
Net fixed assets Rs m5,353244 2,191.3%   
Share capital Rs m123227 54.3%   
"Free" reserves Rs m4,3935,441 80.7%   
Net worth Rs m4,5165,668 79.7%   
Long term debt Rs m1,61825 6,472.8%   
Total assets Rs m8,2917,901 104.9%  
Interest coverage x1.1353.3 0.3%   
Debt to equity ratio x0.40 8,124.0%  
Sales to assets ratio x0.50.9 56.2%   
Return on assets %5.116.5 30.9%  
Return on equity %1.822.9 7.6%  
Return on capital %6.334.0 18.5%  
Exports to sales %00.2 0.0%   
Imports to sales %18.436.3 50.6%   
Exports (fob) Rs mNA15 0.0%   
Imports (cif) Rs m7362,465 29.9%   
Fx inflow Rs m015 0.0%   
Fx outflow Rs m7362,677 27.5%   
Net fx Rs m-736-2,662 27.7%   
CASH FLOW
From Operations Rs m997923 108.0%  
From Investments Rs m-461317 -145.6%  
From Financial Activity Rs m-571-481 118.7%  
Net Cashflow Rs m-35759 -4.6%  

Share Holding

Indian Promoters % 32.9 0.0 -  
Foreign collaborators % 0.0 51.1 -  
Indian inst/Mut Fund % 0.2 11.3 1.6%  
FIIs % 0.6 7.2 8.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 66.4 30.4 218.4%  
Shareholders   20,121 21,978 91.6%  
Pledged promoter(s) holding % 36.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare VENUS REMEDIES With:   IPCA LABS  NOVARTIS  DR. DATSONS LABS  ORCHID PHARMA LTD  GSK PHARMA  

Compare VENUS REMEDIES With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Of Rupee's Fall, China's Investment Growth, and Top Stocks in Focus Today(Pre-Open)

On Tuesday, Indian share markets ended the day on a positive note with gains were largely seen in the healthcare sector, realty sector and energy sector.

Related Views on News

VENUS REMEDIES Announces Quarterly Results (4QFY18); Net Profit Down 307.2% (Quarterly Result Update)

Jun 12, 2018 | Updated on Jun 12, 2018

For the quarter ended March 2018, VENUS REMEDIES has posted a net profit of Rs 94 m (down 307.2% YoY). Sales on the other hand came in at Rs 932 m (up 16.8% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

How to Make Big Profits by Following India's Best Investors(The 5 Minute Wrapup)

Aug 3, 2018

In a time when stocks recommended by so-called 'gurus of the market' are crashing, let Kunal Thanvi guide you to the best gurus...and their best stocks.

The Biggest Mistake You Can Make in this Market (and 3 Stocks to Buy Now!)(Profit Hunter)

Aug 3, 2018

This price pattern can help you identify stocks on the verge of a turnaround.

Does This Indicator Tell Us the Sensex is Headed for a Correction?(Vivek Kaul's Diary)

Aug 3, 2018

To what extent have foreign flows influenced Indian stock markets? How do we see it panning out now?

Why HDFC Equity Fund Disappointed Its Investors(Outside View)

Aug 9, 2018

Though popular, HDFC Equity Fund is not among the best performers anymore. Here is the reason behind its underperformance that has left investors disappointed.

HDFC AMC Makes 65% Listing Gains! Should It Attract Mutual Fund Investors?(Outside View)

Aug 8, 2018

PersonalFN explains if investors should invest in schemes of HDFC Mutual Fund looking at the listing gains of HDFC AMC.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

VENUS REMEDIES SHARE PRICE


Aug 14, 2018 (Close)

TRACK VENUS REMEDIES

  • Track your investment in VENUS REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON VENUS REMEDIES

VENUS REMEDIES 5-YR ANALYSIS

COMPARE VENUS REMEDIES WITH

MARKET STATS